Selective in Vitro Expansion of HLA Class I-restricted HIV-1 Gag-specific CD8+ T Cells: Cytotoxic T-lymphocyte Epitopes and Precursor Frequencies
Overview
Affiliations
Objective: To identify HIV-1 Gag cytotoxic T-lymphocyte (CTL) epitopes and HLA restriction of their recognition, and to define precursor frequencies of HIV-1 Gag-specific CTL in the blood of seropositive individuals.
Methods: B-lymphoblastoid cell lines (B-LCL) infected with recombinant vaccinia viruses (rVV) containing a gene coding for HIV-1 Gag (rVV-Gag) were fixed with paraformaldehyde (PFA) and used as antigen-presenting cells (APC) to stimulate peripheral blood mononuclear cells (PBMC) from asymptomatic HIV-seropositive individuals. Specific CTL activity was determined in 51Cr-release assays using B-LCL as targets after infection with rVV-Gag or after pulsing with partially overlapping peptides spanning the Gag sequence.
Results: In vitro stimulation resulted in an increased number of CD8+ T cells and CD45R0+ and HLA-DR+ cells. Gag-specific cytotoxicity, mediated predominantly by HLA class I-restricted CD8+ CTL, was observed in all seven individuals studied. Multiple HLA-restricted CTL epitopes were identified with a single culture from one of the individuals. Gag-expressing APC were successfully used as stimulator cells in limiting dilution analysis to determine CTL precursor (CTLp) frequencies.
Conclusion: PFA-fixed rVV-Gag-infected autologous B-LCL can be used as stimulator cells in bulk PBMC cultures to identify CTL epitopes and to determine CTLp frequencies. This method will facilitate the analysis of HIV-1-specific CTL responses in HIV-infected and vaccinated individuals.
Stunnenberg M, van Pul L, Sprokholt J, van Dort K, Gringhuis S, Geijtenbeek T Viruses. 2020; 12(7).
PMID: 32708557 PMC: 7412276. DOI: 10.3390/v12070764.
Schutten M, van Baalen C, Guillon C, Huisman R, Boers P, Sintnicolaas K J Virol. 2001; 75(6):2706-9.
PMID: 11222694 PMC: 115895. DOI: 10.1128/JVI.75.6.2706-2709.2001.
Phenotypic and functional separation of memory and effector human CD8+ T cells.
Hamann D, Baars P, Rep M, Hooibrink B, Klein M, van Lier R J Exp Med. 1997; 186(9):1407-18.
PMID: 9348298 PMC: 2199103. DOI: 10.1084/jem.186.9.1407.
Kersten M, Klein M, Holwerda A, Miedema F, van Oers M J Clin Invest. 1997; 99(7):1525-33.
PMID: 9119996 PMC: 507972. DOI: 10.1172/JCI119315.
Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.
Hosie M, Flynn J J Virol. 1996; 70(11):7561-8.
PMID: 8892875 PMC: 190824. DOI: 10.1128/JVI.70.11.7561-7568.1996.